Salubrent has officially launched the first of many planned state-of-the-art analytical labs, which will be strategically located around the country to flexibly address the changing needs of today’s pharmaceutical and biotech companies. With an emphasis on quality, innovation, and responsiveness, our scientific team will provide the testing stability studies, and analytical methods required for the successful development of the next generation of therapeutics.
Beginning in 2024, Salubrent will launch a new technology-focused contract development and manufacturing organization (CDMO) dedicated to flexible, state-of-the-art aseptic fill & finish solutions. As a full-service CDMO, Salubrent will focus on serving clinical and commercial stage pharmaceutical and biotech companies in need of flexible batch production of sterile injectable products using the latest in fill-finish technologies.
We have created a company focused on the Salubrent Customer Experience by meeting, and exceeding, our customers’ project objectives.
Terry NovakPresident & CEO, Salubrent Pharma Solutions
